- Question from MaryA: Is there any new data indicating that Zometa shows a survival benefit when given to postmenopausal women in the adjuvant setting?
- Answers - Kathy D. Miller, M.D. It's a short answer — no. We have at least three large studies comparing the addition of Zometa or not to the other standard treatments that women have received, that have finished enrolling patients, but we have not yet seen results. Those studies enrolled a much broader group of patients, so they included both premenopausal and postmenopausal women and those who received chemotherapy, but we are still awaiting the results of those studies.
The Ask-the-Expert Online Conference called Updates From the 2009 San Antonio Breast Cancer Symposium featured Kathy Miller, M.D. and Kristin Brill, M.D., F.A.C.S. answering your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
Editor's Note: This conference took place in December 2009.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.